A recent piece in the magazine “Ms.” by journalist Holly Grigg-Spall urges more women to educate themselves about potential health risks concerning the birth control pills Yaz and Beyaz, manufactured by German corporation Bayer.
Ms. Grigg-Spall points out that Yaz became the most popular birth control pill in the U.S. soon after its release in 2006, as the result of a marketing campaign that the federal Food and Drug Administration subsequently ruled to be misleading. The FDA requested that Bayer run “corrective” advertisements.
Ms. Grigg-Spall also provides a summation of Bayer’s alleged attempts to withhold information about higher risks of blood clots associated with Yaz. Two studies conducted with funding from Bayer concluded that there was no higher risk of blood clots, but a number of independent studies found a significant link.
She also mentions an FDA advisory committee that held hearings on the safety of Yaz, Yasmin, and Beyaz, and ultimately voted not to remove it from the market because the benefits allegedly outweigh the risks. It was later revealed that several members of the committee had financial ties to Bayer.